1
|
Wu L, Wei S, Pei D, Yao Y, Xiang Z, Yu E, Chen Z, Du Z, Qu S. Activation of the Akt Attenuates Ropivacaine-Induced Myelination Impairment in Spinal Cord and Sensory Dysfunction in Neonatal Rats. Mol Neurobiol 2023; 60:7009-7020. [PMID: 37523045 DOI: 10.1007/s12035-023-03498-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 07/11/2023] [Indexed: 08/01/2023]
Abstract
Prolonged exposure to local anesthetics (LAs) or intrathecal administration of high doses of LAs can cause spinal cord damage. Intraspinal administration of LAs is increasingly being used in children and neonates. Therefore, it is important to study LA-related spinal cord damage and the underlying mechanism in developmental models. First, neonatal Sprague-Dawley rats received three intrathecal injections of 0.5% ropivacaine, 1% ropivacaine, 2% ropivacaine or saline (90-min interval) on postnatal day 7. Electron microscopy, luxol fast blue staining and behavioral tests were performed to evaluate the spinal neurotoxicity caused by ropivacaine at different concentrations. Western blot analysis and immunostaining was performed to detect the expression changes of p-Akt, Akt, myelin gene regulatory factor (MYRF) and myelin basic protein (MBP) in the spinal cord treated with different concentrations of ropivacaine. Our results showed that 1% or 2% ropivacaine impaired myelination in the spinal cord and induced sensory dysfunction, but 0.5% ropivacaine did not. Moreover, 1% or 2% ropivacaine decreased the expression of p-Akt, MYRF and MBP in the spinal cord. Then, in order to further explore the role of these proteins in this model, the Akt-specific activator (SC79) was intraperitoneally injected 30 min before 2% ropivacaine treatment. Interestingly, SC79-mediated activation of Akt partly rescued ropivacaine-induced myelination impairments and sensory dysfunction. Overall, the results showed that ropivacaine caused spinal neurotoxicity in a dose-dependent manner in neonatal rats and that activation of the Akt partly rescued ropivacaine-induced these changes. These data provide insight into the neurotoxicity to the developing spinal cord caused by LAs.
Collapse
Affiliation(s)
- Lei Wu
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Siwei Wei
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Dongjie Pei
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Yiyi Yao
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Zhen Xiang
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Eryou Yu
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Zheng Chen
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China
| | - Zhen Du
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China.
| | - Shuangquan Qu
- Department of Anesthesiology, Hunan Children's Hospital, No.86 Ziyuan Rd, Changsha, 410007, Hunan, China.
| |
Collapse
|
2
|
Analysis of the long non-coding RNA and mRNA expression profiles associated with lidocaine-induced neurotoxicity in the spinal cord of a rat model. Neurotoxicology 2022; 90:88-101. [DOI: 10.1016/j.neuro.2022.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 01/19/2022] [Accepted: 03/06/2022] [Indexed: 11/21/2022]
|
3
|
Zhang Z, Wang J, Song Z, Wang Y, Cheng Z, Guo Q, Wang E, Jian Y, Wu L. Downregulation of microRNA-199a-5p alleviated lidocaine-induced sensory dysfunction and spinal cord myelin lesions in a rat model. Toxicol Lett 2021; 336:1-10. [PMID: 33166664 DOI: 10.1016/j.toxlet.2020.11.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 10/29/2020] [Accepted: 11/03/2020] [Indexed: 01/17/2023]
Abstract
Lidocaine induces neurotoxicity in the spinal cord, but the underlying mechanisms remain unclear. In this study, we evaluated the effects of miR-199a-5p on 10 % lidocaine neurotoxicity. Increased expression of miR-199a-5p in the spinal cord of rats treated with 10 % lidocaine was assessed by qRT-PCR. Furthermore, after miR-199a-5p antagomir administration, the sensory dysfunction and myelin sheath lesions (evaluated by semithin sections stained with toluidine blue, electron microscopy, g-ratios and myelin thickness) induced by 10 % lidocaine were alleviated. Myelin regulatory factor (MYRF), a key molecule of myelin sheath development, was predicted to be a target gene of miR-199a-5p by the TargetScan and miRBase databases. MYRF and its downstream factors myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG) were significantly decreased after intrathecal 10 % lidocaine administration. Moreover, these changes were reversed after miR-199a-5p antagomir administration. FISH-immunofluorescence showed coexpression of miR-199a-5p and MYRF in the spinal cord white matter of rats. A luciferase reporter assay further demonstrated the functional association between miR-199a-5p and MYRF. Overall, miR-199a-5p upregulation is involved in 10 % lidocaine-induced spinal cord toxicity through regulation of MYRF. Therefore, downregulating miR-199a-5p expression may be a potential strategy to ameliorate spinal cord neurotoxicity induced by 10 % lidocaine.
Collapse
Affiliation(s)
- Zhong Zhang
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - Jian Wang
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - Zongbin Song
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - Yunjiao Wang
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - Zhigang Cheng
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - Qulian Guo
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - E Wang
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China
| | - Yanping Jian
- Department of Anesthesiology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, 410008, Changsha City, Hunan Province, China.
| | - Lei Wu
- Department of Anesthesiology, Hunan Children's Hospital, No. 86 Ziyuan Road, 410007, Changsha City, Hunan Province, China.
| |
Collapse
|
4
|
González-Cano R, Montilla-García Á, Ruiz-Cantero MC, Bravo-Caparrós I, Tejada MÁ, Nieto FR, Cobos EJ. The search for translational pain outcomes to refine analgesic development: Where did we come from and where are we going? Neurosci Biobehav Rev 2020; 113:238-261. [PMID: 32147529 DOI: 10.1016/j.neubiorev.2020.03.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 02/06/2020] [Accepted: 03/04/2020] [Indexed: 12/11/2022]
Abstract
Pain measures traditionally used in rodents record mere reflexes evoked by sensory stimuli; the results thus may not fully reflect the human pain phenotype. Alterations in physical and emotional functioning, pain-depressed behaviors and facial pain expressions were recently proposed as additional pain outcomes to provide a more accurate measure of clinical pain in rodents, and hence to potentially enhance analgesic drug development. We aimed to review how preclinical pain assessment has evolved since the development of the tail flick test in 1941, with a particular focus on a critical analysis of some nonstandard pain outcomes, and a consideration of how sex differences may affect the performance of these pain surrogates. We tracked original research articles in Medline for the following periods: 1973-1977, 1983-1987, 1993-1997, 2003-2007, and 2014-2018. We identified 606 research articles about alternative surrogate pain measures, 473 of which were published between 2014 and 2018. This indicates that preclinical pain assessment is moving toward the use of these measures, which may soon become standard procedures in preclinical pain laboratories.
Collapse
Affiliation(s)
- Rafael González-Cano
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain.
| | - Ángeles Montilla-García
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain.
| | - M Carmen Ruiz-Cantero
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain.
| | - Inmaculada Bravo-Caparrós
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain.
| | - Miguel Á Tejada
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain; IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
| | - Francisco R Nieto
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain.
| | - Enrique J Cobos
- Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; Institute of Neuroscience, Biomedical Research Center, University of Granada, Armilla, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; Teófilo Hernando Institute for Drug Discovery, Madrid, Spain.
| |
Collapse
|